European Psychiatry
June 1, 2022
Jaime Rodrigues, O. Nombora, Luiz Vicente Ribeiro
1 citation
Introduction Obsessive Compulsive Disorder (OCD) is a psychiatric disorder associated with suffering and disability. The serotoninergic system is implicated in the neurobiological processes of OCD and serotonin reuptake inhibitors (SRIs) are the first-line treatment. However, clinical improvement after starting SRIs can take long and patients may not fully recover. Meanwhile, recent data...
European Psychiatry
June 1, 2022
D. Khalifa, L. Rashed, A. Shamseldeen et al.
Introduction Identifying a feasible model of chronic schizophrenia would be valuable for studying the possible underlying mechanism and to investigate emerging treatments. Our hypothesis starts from the observation that combining ketamine with isolation could result in long-lasting neuro-psychological deficits and schizophrenia-like features; thus, it could probably be used as the first model...
European Psychiatry
June 1, 2022
L. Silva, L. Bravo
Introduction Ayahuasca is an hallucinogenic tea prepared from the Amazonian vine Banisteriopsis caapi and the leaves of the plant Psychotria Viridis. Banisteriopsis caapi contains monoamine oxidase inhibitors (MAO) that render the N, N-dimethyltryptamine (DMT) of Psychotria Viridis active. This brew is being used as a sacrament in syncretic religions in urban areas of Brazil and worldwide with...
European Psychiatry
June 1, 2022
Bernhard T Baune, Z. Susam, V. Falcone et al.
Introduction Psychiatric emergencies in Major Depressive Disorder (MDD) are characterised by multiple types of symptoms including risk of self-harm and suicidal ideation. S-ketamine intranasally (Spravato) has recently been shown to help alleviate symptoms during depressive emergencies. In this case-series, we detail the clinical effects and usability of S-ketamine applied intranasally in a...
European Psychiatry
June 1, 2022
A. Fraga, B. Mesquita, João Facucho-Oliveira et al.
Introduction Major depressive disorder (MDD) is a highly prevalent clinical condition with a leading cause of disability worldwide. The currently available therapeutic agents have important limitations regarding side effects, partial or non-responsiveness. Patients are considered to have treatment-resistant depression (TRD) if there is no effect or minimal effectiveness after receiving adequate...
European Psychiatry
June 1, 2022
E. Frecska, A. Kazai, P. Bokor et al.
Introduction After a long moratorium since the Controlled Substances Act was passed in 1970, there has been a resurgence of research on the potential therapeutic benefits of psychedelic (PE) compounds. It has been widely believed that the PE effect is a result of the interaction between the drug and the mindset of the patient (the “set”) with the external physical and social conditions (the...
European Psychiatry
June 1, 2022
H. Yaniv, V. Savlev
Introduction There are some patients that remain resistant to treatment for major depressive disorder - who were treated with two or more different medications, and did not demonstrate any improvement in their mental-state. These patients can be treated with a new treatment – Esketamine. The recommended Esketamine treatment protocol includes 8-treatment sessions, each session lasts about two...
European Psychiatry
June 1, 2022
S. Pratas Penedos, M.j. Freire, I. Fonseca et al.
IntroductionPTSD is a chronic, debilitating condition with limited treatment efficacy. Accessing traumatic memories often leads to overwhelming distress, impacting treatment process. Current approved pharmacological treatments have exhibited small to moderate effects when compared with placebo. Evidence suggests 3,4,-methylene-dioxymethamphetamine(MDMA)-assisted psychotherapy as a viable option...
European Psychiatry
June 1, 2022
Fabiana Corsi-Zuelli, C. Loureiro, Rosana Shuhama et al.
Introduction We have previously shown that the association between frequent cannabis use and psychosis is more likely in subgroups with low-grade inflammation than subgroups without (PMID: 33736715). The role of immune-related polymorphisms remains unknown. Objectives To explore whether polymorphisms affecting the function of key immune regulatory proteins moderate the association between...
European Psychiatry
June 1, 2022
M. Barbosa, R. Guedes
IntroductionEsketamine is an S-enantiomer of ketamine approved by the EMA for treatment-resistant depression (TRD). As an NMDA receptor antagonist, its administration results in increase of glutamate release and AMPA receptor activation, supporting both rapid-onset and long-term antidepressant effects. Short-term tolerability seems acceptable but major concerns remain regarding long-term...
European Psychiatry
June 1, 2022
M. Gonçalves, J. Romão, R. André et al.
Introduction Neurocognitive deficits amongst patients with schizophrenia are considered one of schizophrenia’s central features. These deficits appear to be present from the first episode of psychosis (FEP) and certain cognitive impairments could be components of a genetic vulnerability to schizophrenia. Regarding research on cannabis and cognition in schizophrenia, different studies have...
European Psychiatry
June 1, 2022
J. Sá Couto, B. Da Luz, J. Rodrigues et al.
IntroductionPosttraumatic stress disorder (PTSD) is a psychiatric condition which can be developed following traumatic experience. Treatment guidelines have long considered psychotherapy as a first line treatment. Despite that, PTSD remains an illness with high rates of comorbidity. Therefore, exploring novel therapies is of utmost importance.ObjectivesClarifying methylenedioxymethamphetamine...
European Psychiatry
June 1, 2022
J. Bramness
Even if most people use cannabis without many negative consequences, some experience cannabis related harms. At higher levels of intake, one of these harms could be psychotic symptoms and even cannabis-induced psychosis. During the last years, we have seen increased treatment seeking for cannabis use disorders in Europe. Parallel with this increase we have seen an increase in the incidence of...
European Psychiatry
June 1, 2022
B. Leal, D. Vila-Chã, S. Garcia et al.
Introduction Nitrous oxide (NO), also known as “laughing gas” is a colorless gas used as an anesthetic, a propellant in some foods, an engine performance enhancer and a recreational drug. When inhaled, it is known to provoke a rapid feeling of euphoria or excitement for a short period of time, dissociative phenomena and sometimes laughter. As its fellow anesthetic agent and NMDA-receptor...
European Psychiatry
June 1, 2022
C. Laranjeira, A. Querido
IntroductionChronic pain has a significant impact on individuals’ daily lives, and its control is essential for improving quality of life. In this sense, the practice of Mindfulness is a useful non-pharmacological technique for self-management of chronic pain.ObjectivesThis study aims to identify the level of knowledge regarding the effectiveness of Mindfulness for self-control of pain by...
European Psychiatry
October 28, 2021
L Sala, Philip Gorwood, C Vindreau et al.
Background: This study aimed to investigate the effectiveness of mindfulness-based cognitive therapy (MBCT) as a complementary approach in patients with bulimia nervosa (BN) or binge eating disorder (BED), and to assess how the reduction of the cognitive load of words related to eating disorders (ED) could constitute an intermediate factor explaining its global efficacy. Methods: Eighty-eight...
European Psychiatry
April 1, 2021
Athanasios Markopoulos, Antonio Inserra, Danilo de Gregorio et al.
5 citations
Introduction Autism Spectrum Disorder and Social Anxiety Disorder are mental illnesses characterized by a dysfunction in social behavior (SB); a phenomenon largely mediated by the medial prefrontal cortex (mPFC). Clinical studies have demonstrated that lysergic acid diethylamide (LSD), a partial agonist of the 5-HT 2A receptor, can promote SB. However, its mechanism of action on SB is unknown....
European Psychiatry
April 1, 2021
R. Pinilla, Carmen Rocamora Rodriguez, D. Batet-Sanchez et al.
3 citations
Introduction Ayahusca has potential therapeutic beneffits. Objectives Expose the potential beneffits of ayahuasca from neuropharmacology and clinical existing evidence. Methods A literature review was carried out in the databases pubmed, clinical key and texts of scientific dissemination. Results There´s scientific literature about the potential therapeutic use of ayahuasca in dependencies,...
European Psychiatry
April 1, 2021
I. Figueiredo, Filipa Viegas, F. Ferreira et al.
2 citations
Introduction Post-traumatic stress disorder (PTSD) is often a chronic condition, despite the existence of evidence-based treatment options. Psychotherapy is the designated first line treatment for PTSD, although high rates of psychiatric and medical comorbidity are observed among patients who have undergone treatment. The psychoactive properties of psychedelics may be of particular interest...
European Psychiatry
April 1, 2021
S. Torres
2 citations
Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations. In 1950, after LSD’s discovery by Hofmann, psychedelics enjoyed a short-lived relationship with psychiatry, before prohibitive legislature emerging in response to the recreational use in the mid-1960s....
European Psychiatry
April 1, 2021
Nelson Descalço, Ana Beatriz Medeiros, Cátia Fernandes Santos et al.
1 citation
Introduction Psilocybin is a naturally occurring plant alkaloid in mushrooms and a prodrug of psilocin. It is a serotonin receptor (5-HT2A) agonist and known psychedelic, with similar hallucinatory properties to lysergic acid diethylamide (LSD). It has been identified as a safe and effective option in treatment-resistant depression. Literature focus mainly on its use on depressive but its...
European Psychiatry
April 1, 2021
A. Fraga, Daniel Esteves-Sousa, João Facucho-Oliveira et al.
1 citation
Introduction Major depressive disorder is a highly prevalent clinical condition, affecting more than 300 million individuals worldwide. About 1/3 of patients with MDD fail to achieve remission despite treatment with multiple antidepressants and are considered to have treatment-resistant depression (TRD). Novel antidepressants with rapid and sustained effects on mood and cognition could...
European Psychiatry
April 1, 2021
Clayton Peixoto, Fabiano Santos, Daianne Cardinalli Rêgo et al.
1 citation
Introduction Recently there has been renewal in interest of psychedelic research. Classic psychedelics such as lysergic acid diethylamide (LSD), psilocybin and mescaline act pharmacologically as agonists at the 5-HT2A receptor. The entactogens like methylenedioxymethamphetamine (MDMA), acts as a serotonin, dopamine and noradrenaline agonist. All of these drugs are potential candidates in the...
European Psychiatry
April 1, 2021
Jackelyne Gabrielle Jesus de Miranda, Mario Barbosa, I. Figueiredo et al.
Introduction Classic psychedelics have been administered in sacramental contexts since ancient times. They were of prominent interest within psychiatry and neuroscience in the 1950s to 1960s, but the association between classic psychedelics and the emerging counterculture put an end to their research. Modern research with classic psychedelics has reinitiated interest in the treatment of both...
European Psychiatry
April 1, 2021
B. Van der Kolk
Introduction Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Previous research has led to the designation of 3,4-methylenedioxymethamphetamine (MDMA) as a Breakthrough Therapy for treatment of post-traumatic stress disorder (PTSD) when administered as an adjunct to psychotherapy....